Physician profile
Patrick Thompson
NPI 1922772839
$5,968.16
in general payments reported to CMS, 2019-2025
32 companies · $1,940 in 2025
The $1,940 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $1,064 · 2023: $1,185 · 2024: $1,345 · 2025: $1,940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,406 · Education: $63.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,406.40 |
| Education | $63.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,288.22 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $621.27 | 2022-2025 | |
| Pfizer INC. | $602.92 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $436.68 | 2021-2025 | Hyqvia, Cuvitru, Takhzyro |
| Csl Behring | $389.55 | 2023-2025 | Hizentra, Haegarda |
| Grifols USA, LLC | $280.03 | 2023-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Biocryst US Sales Co., LLC | $229.56 | 2022-2025 | Orladeyo |
| Pharming Healthcare, INC. | $226.10 | 2022-2025 | Ruconest |
| Biomarin Pharmaceutical INC. | $172.17 | 2022-2025 | Palynziq |
| Genentech USA, INC. | $169.41 | 2022-2025 | Xolair |
| Amgen INC. | $159.57 | 2022-2023 | Tezspire |
| Sanofi-Aventis U.S. LLC | $153.94 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $149.48 | 2023-2025 | Dupixent |
| Incyte Corporation | $131.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $125.87 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $122.38 | 2023-2025 | Adbry |
| Glaxosmithkline, LLC. | $112.25 | 2023-2025 | Trelegy Ellipta |
| Octapharma USA, INC. | $91.91 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Ars Pharmaceuticals Operations, INC. | $68.38 | 2025 | Neffy |
| Blueprint Medicines Corporation | $59.65 | 2022-2025 | Ayvakit |
| Galderma Laboratories, L.P. | $51.45 | 2025 | Nemluvio |
| Bio Products Laboratory USA, INC. | $48.38 | 2023 | Gammaplex, Coagadex |
| Kaleo, INC. | $48.12 | 2022-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.14 | 2021-2022 | |
| Alk-Abello, INC | $33.22 | 2023 | Alternaria Tenuis, Histamine Positive, Standardized Mite D. Farinae |
| Lilly USA, LLC | $32.91 | 2025 | Ebglyss, Taltz |
| Aimmune Therapeutics, INC. | $24.63 | 2022 | |
| Kedrion Biopharma, INC. | $23.98 | 2024 | Koate, Kedrab, Gammaked |
| Cycle Pharmaceuticals INC | $17.99 | 2025 | Sajazir |
| Covis Pharma Gmbh | $17.46 | 2023 | |
| Gc Biopharma USA, INC. | $16.72 | 2024 | Alyglo |
| Ionis Pharmaceuticals, INC. | $15.43 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.